Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on October 4, 2018, reporting events that occurred on September 28, 2018. The filing details the entry into a material definitive agreement involving a secured convertible promissory note and the issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
- Debt Instrument: Secured Convertible Promissory Note with an original principal amount of $3,170,000.
- Interest Rate: 10% per annum.
- Maturity Date: September 28, 2019.
- Net Proceeds: $3,000,000 received after original issue discount and legal fees.
- Equity Issuance: 500,000 shares of Common Stock ("Origination Shares") issued to the lender.
- Conversion Price: $0.30 per share.
- Collateral: Substantially all company assets, excluding intellectual property.
Material Changes and Terms
The company entered into a financing arrangement with Iliad Research and Trading, L.P. Key terms include:
- Redemption Rights: Beginning March 28, 2019, the lender may redeem the note. The company may pay in cash or convert the redemption amount into shares at the lesser of $0.30 or the Market Price (defined as 80% of the lowest daily VWAP over the preceding 10 trading days).
- Share Reserve: The company must reserve at least 8,900,000 shares of authorized but unissued Common Stock.
- Ownership Cap: Issuances under the agreement are capped at 19.99% of outstanding shares unless stockholder approval is obtained.
- Security Interest Condition: If the company's landlord subordinates its security interest within 30 days of closing, the lender will return the 500,000 Origination Shares.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance or management commentary regarding future operations beyond the terms of the agreement. However, the following risks and contingencies are noted:
- Default Risk: The agreement contains customary events of default that could render all obligations immediately due and payable.
- Encumbrance Risk: Certain assets securing the note are currently encumbered by the company's landlord, creating a potential conflict of interest until subordination is resolved.
- Dilution Risk: The conversion and redemption features could result in significant dilution to existing shareholders, particularly if the market price falls below the $0.30 conversion price.
Investor Verification Checklist
- Verify the current status of the landlord's security interest and whether the Origination Shares have been returned.
- Confirm the total number of shares outstanding as of the closing date to calculate the exact dilution impact of the 19.99% cap.
- Review the company's cash burn rate to assess the ability to service the 10% interest or redeem the note by March 2019.
- Check for any subsequent filings regarding stockholder approval for issuances exceeding the 19.99% threshold.